FRAZIER LIFE SCIENCES MANAGEMENT, LP
Adviser information for FRAZIER LIFE SCIENCES MANAGEMENT, LP last updated from Form ADV on March 30th, 2024. Select data displayed; additional Form ADV, Form D, Form 13F and other data is available from the Fincoded API.
Advisory Business
Type of Organization | Limited Partnership |
---|---|
Fiscal Year End | DECEMBER |
Legal Location | Delaware, United States |
Employees
Total Number of Employees | 53 |
---|---|
Investment Advisory/Research | 37 |
Registered Broker-Dealer Representatives | 0 |
Registered State Investment Advisers | 0 |
Licensed Agents of an Insurance Company | 0 |
No. of Firms/People that Solicit Clients | 0 |
RAUM
Provides Management of Securities Portfolios | Yes |
---|
Type | Accounts | RAUM |
---|---|---|
Discretionary | 8 | $3.6B |
Non-Discretionary | 0 | $0 |
Total | 8 | $3.6B |
Clients
Type | Number | RAUM |
---|---|---|
Individuals | 0 | $0 |
HNW Individuals | 0 | $0 |
Banking or thrift institutions | 0 | $0 |
Investment companies | 0 | $0 |
Business development companies | 0 | $0 |
Pooled investment vehicles | 8 | $3.6B |
Pension and profit sharing plans | 0 | $0 |
Charitable organizations | 0 | $0 |
State or municipal gov entities | 0 | $0 |
Other investment advisers | 0 | $0 |
Insurance companies | 0 | $0 |
Sovereign wealth funds and foreign official institutions | 0 | $0 |
Corporations or other businesses | 0 | $0 |
Other | 0 | $0 |
Type | Number |
---|---|
No. of Non-RAUM Clients | 0 |
No. of Non-U.S. Clients | 0 |
No. of Financial Planning Clients | 0 |
Services
Advisory Services | Portfolio management for pooled investment vehicles |
---|---|
Compensation | % of AUMPerformance-based fees |
Principal Office
1001 PAGE MILL ROADBUILDING 4, SUITE B
PALO ALTO
CA
United States
Monday - Friday, 8AM - 5PM
Tel: 650-325-5156, Fax: None
Websites
Chief Compliance Officer
STEVE BAILEY
CFO
601 UNION STREET
SUITE 3200
SEATTLE
WA
United States
Tel:
206-254-1132
S*****@********************M
(Full email address available in API data)
Regulatory Contact
DAN ONTIVEROS
DIRECTOR OF COMPLIANCE
601 UNION STREET
SUITE 3200
SEATTLE
WA
United States
Tel:
516-521-6874
D************@********************M
(Full email address available in API data)
Industry Affiliates
FHM LIFE SCIENCES VIII, L.P. | Sponsor, GP, manager of pooled investment vehicles |
FHM VII, L.P. | Sponsor, GP, manager of pooled investment vehicles |
FHMLS IX, L.P. | Sponsor, GP, manager of pooled investment vehicles |
FHMLS X, L.P. | Sponsor, GP, manager of pooled investment vehicles |
FHMLS XI, L.P. | Sponsor, GP, manager of pooled investment vehicles |
FHMLSP OVERAGE, L.P. | Sponsor, GP, manager of pooled investment vehicles |
FHMLSP, L.P. | Sponsor, GP, manager of pooled investment vehicles |
Private Funds
Name | Type | Assets $USD | Min Investment $USD | No. Owners |
---|---|---|---|---|
FRAZIER HEALTHCARE VII-A, L.P. | Private Equity Fund | $16.1M | $5.0M | 5 |
FRAZIER HEALTHCARE VII, L.P. | Private Equity Fund | $56.6M | $5.0M | 39 |
FRAZIER LIFE SCIENCES IX, L.P. | Venture Capital Fund | $404.3M | $3.0M | 54 |
FRAZIER LIFE SCIENCES PUBLIC FUND, L.P. | Hedge Fund | $900.4M | $5.0M | 119 |
FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P. | Hedge Fund | $281.4M | $1.0M | 61 |
FRAZIER LIFE SCIENCES VIII, L.P. | Venture Capital Fund | $161.2M | $3.0M | 45 |
FRAZIER LIFE SCIENCES X, L.P. | Private Equity Fund | $566.9M | $3.0M | 72 |
FRAZIER LIFE SCIENCES XI, L.P. | Venture Capital Fund | $316.1M | $5.0M | 99 |
Control Persons
Name | Type | Entity | Title | Since | Ownership |
---|---|---|---|---|---|
BAILEY, STEVE, RAY | Individual | – | CHIEF FINANCIAL OFFICER & CHIEF COMPLIANCE OFFICER | 11/2021 | < 5% |
TOPPER, JAMES, NEWMAN | Individual | – | MANAGING PARTNER | 11/2021 | < 5% |
HERON, PATRICK, JAMES | Individual | – | MANAGING PARTNER | 11/2021 | < 5% |
ESTES, DANIEL | Individual | – | GENERAL PARTNER | 11/2021 | < 5% |
BRUSH, JAMES | Individual | – | GENERAL PARTNER & PORTFOLIO MANAGER | 11/2021 | < 5% |
CHA, ALBERT, (NMN) | Individual | – | MANAGING PARTNER | 11/2021 | < 5% |
GALENA HOLDINGS, LLC | Domestic Entity | – | LIMITED PARTNER | 11/2021 | 50-75% |
TOPPER FAMILY, LLC | Domestic Entity | – | LIMITED PARTNER | 11/2021 | 50-75% |
HERON, PATRICK, JAMES | Individual | GALENA HOLDINGS, LLC | MEMBER | 01/2021 | > 75% |
TOPPER, JAMES, NEWMAN | Individual | TOPPER FAMILY, LLC | MEMBER | 01/2021 | > 75% |
FRAZIER LIFE SCIENCES MANAGEMENT, L.L.C. | Domestic Entity | – | GENERAL PARTNER | 11/2021 | < 5% |
No. Employees, Historic
RAUM, Historic
No. Clients, Historic
Holdings
From latest 13F, filed August 15th, 2024 for period ending June 30th, 2024
Name | Class | Value $USD | # Shares | Private Fund |
---|---|---|---|---|
89BIO INC | COM | 8M | 1M | – |
ACADIA PHARMACEUTICALS INC | COM | 8M | 470K | – |
ACLARIS THERAPEUTICS INC | COM | 291K | 264K | – |
ADVERUM BIOTECHNOLOGIES INC | COM NEW | 7M | 1M | – |
AGIOS PHARMACEUTICALS INC | COM | 38M | 872K | – |
ALLOGENE THERAPEUTICS INC | COM | 7M | 3M | – |
AN2 THERAPEUTICS INC | COM | 4M | 2M | – |
ANAPTYSBIO INC | COM | 54M | 2M | – |
APPLIED THERAPEUTICS INC | COM | 11M | 2M | – |
ARCUTIS BIOTHERAPEUTICS INC | COM | 82M | 9M | – |
ARVINAS INC | COM | 8M | 285K | – |
AUTOLUS THERAPEUTICS PLC | SPON ADS | 16M | 5M | – |
BRIDGEBIO PHARMA INC | COM | 92M | 4M | – |
CEREVEL THERAPEUTICS HLDNG I | COM | 16M | 393K | – |
CG ONCOLOGY INC | COM | 24M | 770K | – |
COGENT BIOSCIENCES INC | COM | 8M | 937K | – |
DESIGN THERAPEUTICS INC | COM | 4M | 1M | – |
DISC MEDICINE INC | COM | 79M | 2M | – |
EDGEWISE THERAPEUTICS INC | COM | 67M | 4M | – |
ELEVATION ONCOLOGY INC | COM | 8M | 3M | – |
ERASCA INC | COM | 38M | 16M | – |
HILLEVAX INC | COM | 154M | 11M | – |
IMMATICS N.V | SHS | 13M | 1M | – |
IMMUNOCORE HLDGS PLC | ADS | 4M | 109K | – |
KALVISTA PHARMACEUTICALS INC | COM | 43M | 4M | – |
KRYSTAL BIOTECH INC | COM | 182M | 988K | – |
MACROGENICS INC | COM | 13M | 3M | – |
MEREO BIOPHARMA GROUP PLC | SPON ADS | 16M | 4M | – |
MERUS N V | COM | 22M | 373K | – |
METAGENOMI INC | COM | 1M | 246K | – |
MIRUM PHARMACEUTICALS INC | COM | 222M | 6M | – |
NEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | 235M | 12M | – |
NEWAMSTERDAM PHARMA COMPANY | *W EXP 11/22/202 | 4M | 500K | – |
ORIC PHARMACEUTICALS INC | COM | 29M | 4M | – |
PEPGEN INC | COM | 24M | 2M | – |
PHATHOM PHARMACEUTICALS INC | COM | 104M | 10M | – |
PUMA BIOTECHNOLOGY INC | COM | 10M | 3M | – |
REVOLUTION MEDICINES INC | COM | 39M | 997K | – |
RHYTHM PHARMACEUTICALS INC | COM | 97M | 2M | – |
ROCKET PHARMACEUTICALS INC | COM | 34M | 2M | – |
SAVARA INC | COM | 33M | 8M | – |
SILENCE THERAPEUTICS PLC | ADS | 22M | 1M | – |
SOLENO THERAPEUTICS INC | COM | 36M | 876K | – |
TARSUS PHARMACEUTICALS INC | COM | 43M | 2M | – |
TREVI THERAPEUTICS INC | COM | 22M | 7M | – |
TYRA BIOSCIENCES INC | COM | 13M | 832K | – |
ULTRAGENYX PHARMACEUTICAL IN | COM | 17M | 425K | – |
VAXCYTE INC | COM | 78M | 1M | – |
VERONA PHARMA PLC | SPONSORED ADS | 48M | 3M | – |